Amgen
AMGN
$324.39
-0.59%
Amgen Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics across a broad range of serious illnesses, including oncology, cardiovascular disease, bone health, neuroscience, and inflammation. The company operates as a mature biopharmaceutical giant with a deep and diversified portfolio of blockbuster drugs and a growing biosimilar business. The current investor narrative is dominated by the integration and performance of its 2023 Horizon Therapeutics acquisition, which expanded its rare disease portfolio, and by navigating a complex regulatory and pricing environment, as highlighted by recent headlines concerning potential 100% drug tariffs and new FDA safety warnings for its drug Tavneos.…
AMGN
Amgen
$324.39
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating: Hold. The core thesis is that Amgen's attractive forward valuation and strong cash flow are currently offset by high leverage and near-term operational/regulatory uncertainties, warranting a neutral stance pending clearer evidence of successful integration and debt management.
Supporting evidence includes a compelling forward P/E of 13.91x, representing a material discount to the industry average, and an implied price target in the mid-$380s based on the average EPS estimate of $27.58. The company's robust cash generation is undeniable, with TTM FCF of $8.1 billion supporting its 2.9% dividend yield. However, these positives are counterbalanced by a debt-to-equity ratio of 6.31 and inconsistent quarterly net margins, which fell to 13.47% in Q4 from 33.65% in Q3.
The thesis would upgrade to a Buy if the forward P/E compressed further toward 12x on sustained earnings growth, or if the company announced a credible debt reduction plan that lowers the D/E ratio below 5.0. It would downgrade to a Sell if revenue growth decelerates below 5% YoY, or if net margins consistently fall below 15%. Relative to its history and peers, the stock appears fairly valued, trading at a trailing P/E in line with the industry average, implying the market has already priced in the current balance of risks and growth prospects.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a classic 'value trap' scenario: its valuation appears cheap on a forward basis, but this discount is justified by substantial balance sheet risk and near-term operational uncertainties. The base case of modest upside to the $380s is most probable, contingent on the company hitting its earnings targets without major setbacks. The stance would upgrade to bullish on clear evidence of deleveraging and sustained double-digit EPS growth, or downgrade to bearish if net margins deteriorate further or debt costs rise sharply. Investors are essentially being paid a 2.9% yield to wait for clarity on whether cash flows can overcome the debt burden.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $421.71 and implied upside of +30.0% versus the current price.
Average Target
$421.71
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$260 - $422
Analyst target range
The stock is covered by 13 analysts, with recent institutional ratings showing a mix of Buy, Hold/Neutral/Equal Weight, and Outperform actions, with no outright Sell ratings, indicating a consensus that leans cautiously optimistic. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $27.58 for the coming period, which, when combined with the forward P/E of 13.91x, implies a potential price target in the mid-$380s, suggesting meaningful upside from the current $326.31 price if those earnings are realized. The target range is wide, with estimated EPS spanning from a low of $26.66 to a high of $28.94, reflecting uncertainty around revenue execution, margin trajectory, and the successful integration of Horizon; the high-end targets likely assume successful pipeline advancements and tariff exemptions, while the low-end may price in competitive pressures, safety warnings like the one for Tavneos, or broader macro headwinds.
Bulls vs Bears: AMGN Investment Factors
The evidence currently tilts slightly bearish in the near term, primarily due to severe technical breakdown, high financial leverage, and emerging regulatory risks that overshadow the company's strong fundamental cash generation and attractive forward valuation. The most critical tension in the investment debate is whether Amgen's robust cash flows (TTM FCF of $8.1B) can sustainably manage its massive debt burden (D/E of 6.31) while simultaneously navigating pipeline integration and external regulatory shocks. If cash flow growth accelerates and debt is reduced, the compelling forward P/E of 13.91x will drive significant upside; however, if interest expenses rise or growth stalls, the high leverage will amplify downside risks.
Bullish
- Strong Forward P/E Discount: Amgen's forward P/E of 13.91x is a significant discount to its trailing P/E of 22.84x and is below the implied industry average of 22x. This suggests the market is pricing in a conservative earnings outlook, creating potential for multiple expansion if the company delivers on its estimated EPS of $27.58.
- Robust Cash Generation: The company generates substantial free cash flow, with TTM FCF of $8.1 billion and quarterly operating cash flow of $4.68 billion. This strong cash generation provides ample capacity to service its high debt load, fund dividends (payout ratio 66.5%), and invest in the business, underpinning financial resilience.
- High Gross Margin Business: Amgen maintains exceptional gross margins, with Q4 2025 reaching 81.91%. This demonstrates the pricing power and operational efficiency of its biotechnology portfolio, providing a wide moat to absorb cost pressures and fund R&D, which totaled $2.15 billion in the same quarter.
- Positive Revenue Growth Trajectory: Q4 2025 revenue grew 8.91% year-over-year to $9.896 billion, driven by newer launches and the Horizon portfolio. Analyst estimates project average revenue of $42.8 billion for the coming period, indicating expectations for continued top-line expansion despite lumpy quarterly results.
Bearish
- Extremely High Financial Leverage: The company's debt-to-equity ratio of 6.31 indicates a heavily leveraged balance sheet, primarily from the Horizon acquisition. This high leverage increases financial risk, constrains strategic flexibility, and makes the company more sensitive to rising interest rates, with quarterly interest expense already at $653 million.
- Sharp Recent Underperformance: The stock has significantly underperformed the market, down 11.61% over three months versus the S&P 500's gain of 8.42%, resulting in a -20.03 relative strength score. This technical breakdown from recent highs near $391 suggests a loss of investor confidence and negative momentum.
- Inconsistent Bottom-Line Results: Net income and margins have shown high volatility, with Q4 2025 net margin at 13.47% plunging from 33.65% in Q3. This inconsistency, driven by acquisition costs and other expenses, creates earnings uncertainty and complicates valuation, as seen in the wide trailing P/E range from 11.36x to 56x.
- Regulatory and Safety Headwinds: Recent news highlights material risks, including an FDA warning about fatal liver risks linked to Tavneos and the threat of 100% tariffs on imported drugs for companies without pricing deals. These events introduce significant commercial, regulatory, and competitive uncertainties that could pressure future growth.
AMGN Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 11.61% over the past three months and 6.29% over the past month, significantly underperforming the broader market which gained 8.42% and 5.6% over the same periods, respectively. Currently trading at $326.31, the price sits approximately 16.6% below its 52-week high of $391.29 and 21.9% above its 52-week low of $267.73, positioning it in the lower-middle portion of its annual range, suggesting a loss of momentum but not yet at deep value levels. Recent momentum is decisively negative and diverging sharply from the longer-term positive trend, as the stock's 1-year gain of 20.10% is being eroded by the recent sharp pullback, signaling a potential trend reversal or a significant correction within the broader uptrend, exacerbated by a relative strength reading of -20.03 against the S&P 500 over three months. Key technical support is anchored at the 52-week low of $267.73, while immediate resistance lies at the recent high near $391.29; a sustained break below the $320-$330 consolidation zone could signal a test of lower support, whereas reclaiming the $370 level would be needed to restore bullish momentum. The stock's beta of 0.435 indicates it is significantly less volatile than the market, which has provided downside protection during the recent sell-off but may also limit the velocity of any recovery.
Beta
0.43
0.43x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$268-$391
Price range past year
Annual Return
+19.1%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +4.0% |
| 3m | -13.1% | +8.2% |
| 6m | -5.3% | +11.5% |
| 1y | +19.1% | +24.3% |
| ytd | -1.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Revenue growth has been positive but decelerating, with Q4 2025 revenue of $9.896 billion representing an 8.91% year-over-year increase; however, this follows a more volatile quarterly pattern where Q3 2025 revenue was $9.557 billion and Q2 was $9.167 billion, indicating some lumpiness in sales, with growth drivers including newer launches like Tezspire and the Horizon portfolio offsetting pressures on mature products. The company remains solidly profitable, posting Q4 2025 net income of $1.333 billion and an impressive gross margin of 81.91%, though net margins have fluctuated significantly quarter-to-quarter from 33.65% in Q3 to 13.47% in Q4, reflecting the impact of acquisition-related costs and other expenses on bottom-line consistency. Financial health is characterized by a strong cash-generative business, with trailing twelve-month free cash flow of $8.1 billion, but this is offset by a highly leveraged balance sheet evidenced by a debt-to-equity ratio of 6.31, indicating the company relies heavily on debt financing, particularly following the Horizon acquisition, though its robust operating cash flow of $4.684 billion in Q3 2025 provides ample coverage for interest and dividends.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given the consistently positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 22.84x, while the forward P/E is significantly lower at 13.91x, indicating the market expects a substantial earnings recovery or growth in the coming year. Compared to the provided industry average P/E of 22x (implied from the data stating a 59% premium would equate to a 35x PE vs. 22x average), Amgen's trailing multiple is roughly in line, while its forward multiple represents a material discount, suggesting the market is pricing in more conservative growth or lingering concerns over debt and integration. Historically, the stock's own trailing P/E has ranged widely, from lows near 11.36x in early 2023 to highs above 56x in late 2024; the current 22.84x sits near the midpoint of this multi-year range, suggesting a valuation that is neither excessively optimistic nor pessimistic relative to its own history, balancing its strong cash flow against its elevated leverage.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on Amgen's highly leveraged balance sheet, with a debt-to-equity ratio of 6.31 creating significant interest burden ($653M in Q4) and refinancing risk. Bottom-line volatility is pronounced, as net margin collapsed from 33.65% in Q3 to 13.47% in Q4 2025, indicating earnings are susceptible to large quarterly swings from acquisition costs and other expenses. While revenue growth is positive at 8.91% YoY, it remains dependent on successful integration of the Horizon portfolio and new launches to offset mature product pressures, introducing execution risk.
Market & Competitive Risks are elevated by the stock's premium valuation relative to its own history, trading at a trailing P/E of 22.84x near the midpoint of its wide historical range. External regulatory threats are material, with recent FDA safety warnings for Tavneos and potential 100% drug tariffs creating uncertainty for pricing and market access. Although its low beta of 0.435 provides some insulation from broad market swings, the stock's severe recent underperformance (-20% RS over 3 months) indicates it faces significant sector-specific and company-specific headwinds that could lead to further valuation compression.
Worst-Case Scenario involves a combination of failed Horizon integration, escalating tariff costs, and a safety-related slowdown for key drugs like Tavneos, leading to missed earnings estimates and a credit rating downgrade. This could trigger a re-rating to the bottom of its historical P/E range (near 11x) on lowered earnings, pushing the stock toward its 52-week low of $267.73. From the current price of $326.31, this represents a realistic maximum drawdown of approximately -18%, not accounting for a broader market downturn which could exacerbate losses further given the high financial leverage.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extreme leverage with a debt-to-equity ratio of 6.31 exposes the company to rising interest rates and limits financial flexibility. 2) Operational/Regulatory Risk: Recent FDA safety warnings for Tavneos and potential 100% drug tariffs create uncertainty for product sales and margins. 3) Execution Risk: Successful integration of the large Horizon acquisition is critical for growth but carries significant cost and synergy realization risks. 4) Earnings Volatility: Quarterly net margins have fluctuated wildly, from 33.7% to 13.5%, creating uncertainty around bottom-line consistency.
The 12-month forecast centers on a base case target range of $360-$385 (55% probability), derived from the consensus EPS estimate of $27.58 and the current forward P/E. A bull case to $391-$405 (30% probability) requires successful Horizon integration and tariff exemptions driving earnings to the high end of estimates. A bear case to $268-$320 (15% probability) involves integration failures and regulatory setbacks compressing the multiple toward the 52-week low. The most likely outcome is modest upside as the company executes its plan, but the wide range reflects the high uncertainty surrounding debt and external pressures.
AMGN appears fairly valued relative to peers but undervalued on a forward-looking basis. Its trailing P/E of 22.8x is in line with the industry average, suggesting the market is pricing it appropriately for its current earnings. However, its forward P/E of 13.9x represents a steep discount, indicating the market expects little growth or is assigning a high risk premium due to leverage. This forward discount implies the stock is undervalued if the company meets its EPS estimate of $27.58, but the valuation accurately reflects the elevated balance sheet and integration risks.
AMGN is a conditional buy for patient, risk-tolerant investors. The stock offers a compelling 2.9% dividend yield and trades at a forward P/E of 13.9x, implying significant upside to analyst-derived targets in the $380s if earnings materialize. However, it carries substantial risk from its high debt load (D/E of 6.31) and recent regulatory headwinds. It is a good buy for investors who believe management can successfully integrate the Horizon acquisition and begin deleveraging, but it is not suitable for those seeking low-risk or high-growth investments.
AMGN is best suited for a long-term investment horizon of 3-5 years. Its low beta of 0.435 and dividend yield make it a poor candidate for short-term trading, as it typically exhibits lower volatility and slower price movements. The long-term horizon is necessary to allow management time to pay down debt, realize synergies from the Horizon acquisition, and navigate the current regulatory environment. Short-term investors would be better served by more volatile, catalyst-driven biotech stocks, while income and value investors can use AMGN as a core, defensive healthcare holding.